-
AMRI to Receive Milestone Payment from Bristol-Myers Squibb for the Initiation of a Phase II Study
Wednesday, May 25, 2011 - 8:02am | 145AMRI (NASDAQ: AMRI) today announced that it will receive a $3 million milestone payment from Bristol-Myers Squibb Company (NYSE: BMY) resulting from a recently initiated Phase 2 clinical trial of an AMRI compound exclusively licensed to Bristol-Myers Squibb. This is the sixth milestone payment...
-
Taglich Brothers Neutral On Pressure BioSciences, Inc.
Wednesday, May 25, 2011 - 7:15am | 140Taglich Brothers has a Neutral rating on shares of Pressure BioSciences, Inc. (NASDAQ: PBIO). In a note to clients, Taglich writes, "We are maintaining our Neutral rating on Pressure BioSciences (NasdaqCM: PBIO) due to heightened concerns about the company's ability to raise sufficient capital to...
-
Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest Cash
Wednesday, May 25, 2011 - 1:27am | 129Below are the top small-cap diagnostic substances stocks on the NYSE and NASDAQ in terms of cash. Immucor Inc (NASDAQ: BLUD) had $274.68 million in total cash and no debt for the latest quarter. AMAG Pharmaceuticals Inc (NASDAQ: AMAG) had $238.23 million in total cash and no debt for the latest...
-
Exelixis Announces Data From a Phase 1 Clinical Trial of Exelixis' Cabozantinib Published in the Journal of Clinical Oncology
Monday, May 23, 2011 - 4:55pm | 121Exelixis, Inc. (NASDAQ: EXEL) today announced the results of the phase 1 clinical trial of cabozantinib in patients with advanced solid tumors or lymphoma have been published in the current issue of the Journal of Clinical Oncology. The publication includes safety data from all 85 patients enrolled...
-
Goldman Sachs Provides Color on CROs, Sell Parexel and Buy Pharmaceutical Product Development
Monday, May 23, 2011 - 9:03am | 358Goldman Sachs provided color on the CRO industry. In a research report published today, Goldman states, "The CRO industry is in a time of transformation as Pharma's approach to R&D spending and outsourcing continues to evolve. Fundamentals in the early-stage and the late-stage environments...
-
Merger Arbitrage Mondays – May 23, 2011
Monday, May 23, 2011 - 2:08am | 4780Merger activity increased last week with five new deals announced and seven closing. You can find all the active deals listed below in our Merger Arbitrage Tool that automatically updates itself during market hours. Deal Statistics: Total Number of Deals Closed in 2011 74 Total Number of Deals...
-
J.P. Morgan Resumes Coverage On Thermo Fisher Scientific With Overweight Rating
Friday, May 20, 2011 - 8:25am | 136According to J.P. Morgan, Thermo Fisher Scientific (NYSE: TMO) coverage is resumed with Overweight rating. J.P. Morgan said that it was previously restricted on Thermo Fisher Scientific (TMO) shares due to J.P. Morgan's involvement in the Dionex transaction announced on December 13, 2010. “With...
-
JP Morgan Raises PT Thermo Fisher Scientific To $72, Resumes Coverage At Overweight
Friday, May 20, 2011 - 7:35am | 30JP Morgan has raised the price target on Thermo Fisher Scientific (NYSE: TMO) from $58 to $72 and resumes coverage with an Overweight rating.
-
Thermo Fisher Scientific Up 4% On Deal News
Thursday, May 19, 2011 - 11:53am | 301Thermo Fisher Scientific Inc Co (NYSE: TMO) shares are jumping this morning, gaining almost 4% on news that the company will pay about $3.5 billion in cash for Swedish company Phadia, a maker of blood test systems for allergy and auto-immune diseases. "The acquisition of Phadia is a major step...
-
Benzinga's Top Pre-Market NASDAQ Gainers
Thursday, May 19, 2011 - 8:35am | 125Glu Mobile Inc (NASDAQ: GLUU) shares surged 5.54% to $3.62 in the pre-market session. GLUU had no debt for the recent quarter. Exelixis Inc (NASDAQ: EXEL) shares advanced 5.49% to $12.30 in the pre-market session. Exelixis' cancer drug cabozantinib was shown to slow prostate cancer and ovarian...
-
Thermo Fisher Scientific to Acquire Phadia for $3.5B
Thursday, May 19, 2011 - 8:04am | 80Thermo Fisher Scientific Inc. (NYSE: TMO) today announced that it has signed a definitive agreement to acquire Phadia, a global leader in allergy and autoimmunity diagnostics, from European private equity firm Cinven, for €2.47 billion (or approximately $3.5 billion) in cash. The transaction, which...
-
Piper Jaffray Maintains Overweight on Sequenom (SQNM)
Thursday, May 19, 2011 - 7:51am | 125Piper Jaffray is out with its report today on Sequenom (NASDAQ: SQNM), maintaining Overweight. In a note to clients, Piper Jaffray writes, "We recently traveled with members of Sequenom's management team and received a favorable business update. Management reiterated T21 time-lines, with a LDT...
-
Piper Jaffray Maintains Overweight Rating On Exelixis
Thursday, May 19, 2011 - 7:51am | 139According to Piper Jaffray, Exelixis (NASDAQ: EXEL) Overweight rating is maintained Piper Jaffray said that abstracts were published last night for the upcoming American Society of Clinical Oncology (ASCO) meeting in Chicago from June 3rd-7th. “Exelixis has 3 oral presentations at ASCO including...
-
Compugen Discloses Discovery Method for Drug Candidates That Interfere With Protein Conformations
Thursday, May 19, 2011 - 7:04am | 74Compugen Ltd. (NASDAQ: CGEN) announced today the development of a method to identify novel therapeutic candidates to interfere with disease associated protein conformations and protein-protein interactions. This new in silico method relies on the prediction of hidden conformations of the proteins...
-
PPD and Berry Consultants Sign Agreement in Bayesian Statistics
Tuesday, May 17, 2011 - 4:28pm | 95PPD, Inc. (Nasdaq: PPDI) and Berry Consultants, LLC today announced they have entered into a collaboration in the area of Bayesian statistics, providing biopharmaceutical companies a way to improve the speed and quality of decision making for their clinical development programs. As part of the...